Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
31JUL

PABS talks reopen under a deadline

2 min read
10:28UTC

The seventh Intergovernmental Working Group opened in Geneva on 6 July to break the deadlock over pandemic-era vaccine sharing, under a 17 July deadline Lula and Tedros called a deadline, not a milestone.

ScienceDeveloping
Key takeaway

IGWG7 has until 17 July to conclude the PABS annex or defer pandemic-era vaccine sharing a fourth time.

The seventh Intergovernmental Working Group (IGWG7) on the WHO Pandemic Agreement opened in Geneva on Monday 6 July, running to 17 July, to try again on the Pathogen Access and Benefit-Sharing (PABS) annex 1. PABS is the mechanism meant to guarantee that countries which share virus samples receive the vaccines made from them, and it has been deadlocked since the World Health Assembly, WHO's member-state governing body, deferred it in May , with talks stalling again ahead of this session .

On Monday 15 June, Brazilian President Lula and WHO Director-General Tedros Adhanom Ghebreyesus co-signed an open letter to the leaders of the G7, G20 and BRICS, naming 17 July "a deadline, not a milestone." That letter carried the first head-of-state signature on the PABS push; the two earlier extensions bore only WHO's name. The letter set out the three unresolved questions plainly: how benefits are shared, how the system is governed, and how equity is guaranteed.

PABS turns on one trade: manufacturers and rich states hold the production capacity, while the countries where novel pathogens most often emerge hold the samples and want binding access in return. That North-South bargain is the pandemic-era successor to a 2011 influenza-only framework, which itself took four years to negotiate; extending it to every pathogen is the harder task now stalled. A Brazilian president signing the demand signals which side now feels the urgency.

Deep Analysis

In plain English

PABS stands for Pathogen Access and Benefit Sharing. It's the part of the WHO Pandemic Agreement meant to answer a simple question: if a country shares a dangerous virus sample so vaccine makers can study it, what does that country get back once a vaccine exists? Right now there's no binding answer. Countries like DRC share outbreak data and virus samples in real time, but have no guaranteed right to buy the vaccines and treatments that data helps produce. IGWG7, running in Geneva from 6 to 17 July, is the seventh attempt to agree binding rules. Brazil's President Lula and WHO's Director-General set a public deadline in a 15 June letter, hoping a named date succeeds where earlier rounds didn't.

Deep Analysis
Root Causes

IGWG7's deadlock traces to one unresolved clause: what share of real-time vaccine, therapeutic and diagnostic production a manufacturer must reserve for WHO-coordinated distribution during a declared pandemic, before any bilateral advance-purchase agreement is honoured.

Manufacturing states, home to the pharmaceutical companies that would carry that obligation, have resisted a fixed percentage since the clause first appeared in draft text; countries without domestic manufacturing capacity, DRC prominent among them given its real-time Bundibugyo sequence-sharing, treat the same percentage as the entire point of the treaty.

What could happen next?
  • Consequence

    A further missed PABS deadline would leave DRC sharing Bundibugyo sequence data through the current outbreak with no treaty-guaranteed claim on any vaccine or treatment that data helps develop.

First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

WHO· 5 Jul 2026
Read original
Different Perspectives
Chinese health authorities
Chinese health authorities
China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.
US public health authorities
US public health authorities
CIDRAP and Dr Andrew Racine, president of the American Academy of Pediatrics, call 2026's 2,318 confirmed measles cases by 24 July the worst year since 1991's 2,126. Zero deaths against three in 2025 and a 7% hospitalisation rate, down from 11%, show record case counts have not brought record severity.
CEPI
CEPI
CEPI put an rVSV-platform vaccine candidate specific to Bundibugyo ebolavirus into trial-production on 31 July, developed by Hilleman Laboratories with MSD manufacturing and IAVI's reference virus, funded up to $8.5m. Eleven weeks into the third-largest Ebola outbreak on record, this is the first species-matched candidate; the licensed vaccine covers only Zaire ebolavirus.
Médecins Sans Frontières
Médecins Sans Frontières
MSF reports sexual-violence care in Ituri is almost non-existent, with 7 of 14 health centres closed or relocated by fighting, as Panzi Hospital logs 646 new survivors in six months, an 85% rise. Withdrawn US funding for post-exposure prophylaxis has left clinics across three provinces without PEP kits for months, a crisis running alongside Ebola, not caused by it.
DRC health workers at Elikya Ebola Treatment Centre
DRC health workers at Elikya Ebola Treatment Centre
Staff at DRC's Elikya Ebola Treatment Centre walked out on 25 July over unpaid wages, the second such action after Rwampara, while unconfirmed suspects occupy up to 64% of the country's isolation beds awaiting lab results. Workers are absorbing a response that has grown faster than its payroll and its labs.
Uganda's Ministry of Health
Uganda's Ministry of Health
Uganda's ministry says it discharged its last confirmed patient on 16 June, completed every contact's 21-day follow-up, and declared the country Ebola-free on 28 July, exactly 42 days later. It names Hon. Dr Chris Baryomunsi, Minister of Health, as overseeing a 20-case, 2-death outbreak it now considers closed.